Proliposome powder or tablets for generating inhalable liposomes using a medical nebulizer

다국어 초록 (Multilingual Abstract)

Purpose The aim of this study was to develop and compare proliposome powder and proliposome tablet formulations for drug delivery from a Pari-LC Sprint nebulizer.
Methods Proliposome powders were prepared by the slurry method and sorbitol or mannitol carbohydrate carrier were used in a 1:10 and 1:15 w/w lipid phase to carrier ratio. Beclometasone dipropionate (BDP; 2 mol%) was incorporated in the lipid phase. Proliposome powders were compressed into tablets, and liposomes were generated from proliposome powders or tablets within the nebulizer reservoir for subsequent aerosolization.
Results Comparatively, shorter sputtering times were reported for the tablet formulations (≈ < 2.7±0.45 min), indicating uniform aerosolization. Post-nebulization, liposomes size was larger in the nebulizer reservoir in the range of 7.79±0.48 μm–9.73±1.53 μm for both powder and tablet formulations as compared to freshly prepared liposomes (5.38±0.73 μm–5.85±0.86 μm), suggesting liposome aggregation/fusion in the nebulizer’s reservoir. All formulations exhibited more than 80% mass output regardless of formulation type, but greater BDP proportions (circa 50%) were delivered to the Two-stage Impinger when tablet formulations were used. Moreover, the nebulized droplet median size and size distribution were lower for all tablet formulations in comparison to the powder formulations. Proliposome tablet and powdered formulations demonstrated the ability to generate vesicles that sustained the release of BDP.
Conclusion Overall, this study showed that proliposome tablets could be disintegrated within a Pari-LC Sprint nebulizer to generate inhalable aerosol, with high drug output and hence can be manufactured on large scale to overcome the storage problems associated with powder formulations.

참고문헌 (Reference)

1 Hunt CA, "α-Tocopherol retards autoxidation and prolongs the shelf-life of liposomes" 8 : 101-110, 1981

2 Elhissi A, "Vibrating-mesh nebulization of liposomes generated using an ethanol-based proliposome technology" 21 : 173-180, 2011

3 Hallworth GW, "The twin impinger: a simple device for assessing the delivery of drugs from metered dose pressurized aerosol inhalers" 39 : 966-972, 1987

4 Taylor KMG, "The stability of liposomes to nebulisation" 58 : 57-61, 1990

5 O’Callaghan C, "The science of nebulised drug delivery" 52 (52): S31-S44, 1997

6 Bnyan R, "The efect of ethanol evaporation on the properties of inkjet produced liposomes" 28 : 271-280, 2020

7 Khan I, "Surgical tools and medical devices" Springer International Publishing 573-591, 2016

8 Omer HK, "Spray-dried proliposome microparticles for high-performance aerosol delivery using a monodose powder inhaler" 19 : 2434-2448, 2018

9 Saari M, "Pulmonary distribution and clearance of two beclomethasone liposome formulations in healthy volunteers" 181 : 1-9, 1999

10 Girod De Bentzmann S, "Protection of human respiratory epithelium from pseudomonas aeruginosa adherence by phosphatidylglycerol liposomes" 62 : 704-708, 1994

11 Bouchard A, "Properties of sugar, polyol, and polysaccharide water−ethanol solutions" 52 : 1838-1842, 2007

12 Ferron GA, "Properties of aerosols produced with three nebulizers" 114 : 899-908, 1976

13 Payne NI, "Proliposomes: a novel solution to an old problem" 75 : 325-329, 1986

14 Khan I, "Proliposome tablets manufactured using a slurry-driven lipid-enriched powders: development, characterization and stability evaluation" 538 : 250-262, 2018

15 Khan I, "Proliposome powders prepared using a slurry method for the generation of beclometasone dipropionate liposomes" 496 : 342-350, 2015

16 Khan I, "Proliposome powders for the generation of liposomes:the infuence of carbohydrate carrier and separation conditions on crystallinity and entrapment of a model antiasthma steroid" 19 : 262-274, 2018

17 Nasr M, "Pamam dendrimers as aerosol drug nanocarriers for pulmonary delivery via nebulization" 461 : 242-250, 2014

18 Khan I, "Paclitaxel-loaded micro or nano transfersome formulation into novel tablets for pulmonary drug delivery via nebulization" 575 : 118919-, 2020

19 Elhissi AM, "Novel antimicrobial agents and strategies" Wiley 387-406, 2015

20 Waldrep JC, "New aerosol drug delivery systems for the treatment of immune-mediated pulmonary diseases" 34 : 549-561, 1998

21 Godet C, "Nebulized liposomal amphotericin b for treatment of pulmonary infection caused by hormographiella aspergillata: case report and literature review" 182 (182): 709-713, 2017

22 Niven RW, "Nebulization of liposomes. II. The efects of size and modeling of solute release profles" 8 : 217-221, 1991

23 McCallion ONM, "Nebulization of fuids of diferent physicochemical properties with air-jet and ultrasonic nebulizers" 12 : 1682-1688, 1995

24 Bridges PA, "Nebulisers for the generation of liposomal aerosols" 173 : 117-125, 1998

25 Darwis Y, "Nebulisation of rehydrated freezedried beclomethasone dipropionate liposomes" 215 : 113-121, 2001

26 Finlay WH, "Lung delivery of aerosolized dextran" 161 : 91-97, 2000

27 Elhissi A, "Liposomes for pulmonary drug delivery: the role of formulation and inhalation device design" 23 : 362-372, 2017

28 Kontturi L-S, "Light-triggered cellular delivery of oligonucleotides" 11 : 90-, 2019

29 Rojanarat W, "Levofoxacin-proliposomes: opportunities for use in lung tuberculosis" 4 : 385-, 2012

30 Elhissi AM, "Laser difraction and electron microscopy studies on inhalable liposomes generated from particulate-based proliposomes within a medical nebulizer" 12 : 6693-6699, 2012

31 Elhissi AM, "Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers" 58 : 887-894, 2006

32 Steckel H, "Factors afecting aerosol performance during nebulization with jet and ultrasonic nebulizers" 19 : 443-455, 2003

33 Narenji M, "Efect of bilayer fexibility and medium viscosity on separation of liposomes upon stagnation" 13 : 23-34, 2017

34 Elhissi A, "Delivery of liposomes generated from pro liposomes using air-jet, ultrasonic and vibrating-mesh nebulisers" 15 : 261-265, 2005

35 Manca M, "Composition influence on pulmonary delivery of rifampicin liposomes" 4 : 590-, 2012

36 Stewart JCM, "Colorimetric determination of phospholipids with ammonium ferrothiocyanate" 104 (104): 14-, 1980

37 Khan I, "Biomaterial and medical tribology research and development" Woodhead Publishing Limited 395-443, 2013

38 Clay M, "Assessment of Jet nebulisers for lung aerosol therapy" 322 : 592-594, 1983

39 Bridges PA, "An investigation of some of the factors infuencing the jet nebulisation of liposomes" 204 : 69-79, 2000

40 Shirley M, "Amikacin liposome inhalation suspension: a review in mycobacterium avium complex lung disease" 79 : 555-562, 2019

41 Subramanian S, "A simple approach to predict the stability of phospholipid vesicles to nebulization without performing aerosolization studies" 502 : 18-27, 2016

42 Khan I, "A facile and novel approach to manufacture paclitaxel-loaded proliposome tablet formulations of micro or nano vesicles for nebulization" 37 : 116-, 2020

43 Gala RP, "A comprehensive production method of self-cryoprotected nano-liposome powders" 486 : 153-158, 2015